Fenfluramine Other names: 3-trifluoromethyl-N-ethylamphetamine

Chemical formula: C₁₂H₁₆F₃N Molecular mass: 231.257 g/mol PubChem compound: 3337

Therapeutic indications

Fenfluramine is indicated for:

Seizures associated with Dravet syndrome and Lennox-Gastaut syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Fenfluramine is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0,1 mg/kg twice daily in the first week, 0,2 mg/kg twice daily in the second week and thereafter 0.35 mg/kg twice daily

Contraindications

Fenfluramine is contraindicated in the following cases:

Lactation

Aortic or mitral valvular heart disease

at least one of

Aortic valve disorder
Mitral valve disorder

Pulmonary arterial hypertension

Pulmonary hypertensive arterial disease

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors (MAOIs)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.